| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Seljeseth and Tysnes), Haukeland University Hospital; and Division of Medical Statistics (Dr. Vollset), University of Bergen, Norway.
Address correspondence and reprint requests to Dr. Ole-Bjørn Tysnes, Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway; e-mail: obty{at}haukeland.no
OBJECTIVE: To investigate a possible increase in incidence of ALS in Norway.
METHODS: Death certificate data from all deaths in Norway in the period 1961 to 1994 for ALS, PD, and MG were obtained from Statistics Norway and related to population statistics. Data on ALS was obtained on sex, age, and place of death and compared with mortality data in PD and MG for the same period. Data were standardized using the 1990 population as standard population. Poisson regression was used to test for trends in mortality. The data from the death certificates were related to a clinical study performed on ALS in one of the counties during the same period.
RESULTS: The annual mortality of ALS almost doubled during the period studied, rising from 1.38 to 2.54 per 100,000 inhabitants at the end of the study. The increased mortality appeared solely in the population older than 60 years of age, with a peak in mortality in the age group 80 to 84 years. The increase was larger in women than in men, and the ratio between the sexes was 1.32 (men–women, age-adjusted at the end of the study). The mortality in patients with PD showed a similar increase to that seen in ALS, whereas no increase in mortality was observed in patients with a diagnosis of MG. There were considerable differences in ALS mortality in different counties, but no clear regional trends were observed.
CONCLUSION: The authors report increasing ALS mortality. Although the increase in mortality is restricted to the population aged 65 years or older, it cannot be explained by increasing age of the general population alone.
This article has been cited by other articles:
|
|
 |
|
  F. Fang, U. Valdimarsdottir, R. Bellocco, L.-O. Ronnevi, P. Sparen, K. Fall, and W. Ye Amyotrophic Lateral Sclerosis in Sweden, 1991-2005 Arch Neurol, April 1, 2009; 66(4): 515 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chio, G. Mora, A. Calvo, L. Mazzini, E. Bottacchi, R. Mutani, and On behalf of the PARALS Epidemiology of ALS in Italy: A 10-year prospective population-based study Neurology, February 24, 2009; 72(8): 725 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Murphy, S. Quinn, J. Young, P. Parkin, and B. Taylor Increasing incidence of ALS in Canterbury, New Zealand: A 22-year study Neurology, December 2, 2008; 71(23): 1889 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O O'Toole, B J Traynor, P Brennan, C Sheehan, E Frost, B Corr, and O Hardiman Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004 J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 30 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Noonan, M. C. White, D. Thurman, and L.-Y. Wong Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998 Neurology, April 12, 2005; 64(7): 1215 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Desport, P. M Preux, C. Bouteloup-Demange, P. Clavelou, B. Beaufrere, C. Bonnet, and P. P Couratier Validation of bioelectrical impedance analysis in patients with amyotrophic lateral sclerosis Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1179 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mandrioli, P. Faglioni, E. Merelli, and P. Sola The epidemiology of ALS in Modena, Italy Neurology, February 25, 2003; 60(4): 683 - 689. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
